CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study
Closed Solicitation Posted
- Solicitation number
- RFP_75D301-20-R-68127
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- USA
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) is seeking proposals to provide laboratory testing services under solicitation number RFP_75D301-20-R-68127 to support its Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study. Offerors must propose to conduct ELISA, microneutralization, and quantitative IgG assays on residual blood specimens from commercial laboratories across the United States over nine months. Proposals will be evaluated based on the offeror's technical approach, management plan, staffing plan, and relevant experience. Pricing proposals are due by September 7, 2020 and must be submitted via email. Questions from potential offerors must be submitted by August 24, 2020.
This procurement has no set-aside designations and will be conducted full and open. The NAICS code is 541715 and PSC code is D304. Awards may be made to multiple contractors to provide geographic coverage for testing in all 50 states, Washington D.C., and Puerto Rico over the period of performance from October 12, 2020 to June 2021. The total contract value will depend on the number of awards but is estimated to be over $10 million to process approximately 300,000 specimens biweekly. The place of performance will be laboratories within the United States.
Notice text
3 versions
Update #3 · Latest ·
This is a combined synopsis/solicitation for commercial supplies/services prepared in accordance with the format in FAR Subpart 12.6 . This announcement constitutes the only solicitation; proposals are being requested and no additional written solicitation will be issued. The solicitation number is 75D301-20-R-68127.
This solicitation is to obtain laboratory testing services for CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study with an estimated start date of October 12, 2020. This procurement is being conducted full and open with no set aside.
Proposals are due by September 9, 2020, at 5PM EST. Offers shall be submitted via e-mail. (Note: posting modification on August 20, 2020, amended the proposal due date to September 9, 2020.)
UPDATED:
Only one question was submitted in response to this posting. Please see below for question and response.
Question: Under Deliverables, Critical Elements, it states that “Testing will include CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and IgM serological assays" does that mean that CLIA-approved and/or EUA-approved ELISAs only will be accepted?
CDC Response: For Task 1, CDC does not intend to consider non-CLIA/EUA tests. For Tasks 2 and 3, CDC will assess non-CLIA/EUA tests based on performance and alternative availability. However, CLIA/EUA tests will receive preference in our evaluation.
Update #2 ·
This is a combined synopsis/solicitation for commercial supplies/services prepared in accordance with the format in FAR Subpart 12.6 . This announcement constitutes the only solicitation; proposals are being requested and no additional written solicitation will be issued. The solicitation number is 75D301-20-R-68127.
This solicitation is to obtain laboratory testing services for CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study with an estimated start date of October 12, 2020. This procurement is being conducted full and open with no set aside.
Proposals are due by September 9, 2020, at 5PM EST. Offers shall be submitted via e-mail. (Note: posting modification on August 20, 2020, amended the proposal due date to September 9, 2020.)
Questions shall be submitted via e-mail in the attached template no later than August 24, 2020, 5:00 PM EST.
Update #1 ·
This is a combined synopsis/solicitation for commercial supplies/services prepared in accordance with the format in FAR Subpart 12.6 . This announcement constitutes the only solicitation; proposals are being requested and no additional written solicitation will be issued. The solicitation number is 75D301-20-R-68127.
This solicitation is to obtain laboratory testing services for CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study with an estimated start date of October 12, 2020. This procurement is being conducted full and open with no set aside.
Proposals are due by September 7, 2020, at 5PM EST. Offers shall be submitted via e-mail.
Questions shall be submitted via e-mail in the attached template no later than August 24, 2020, 5:00 PM EST.
Files
| File | Type | Posted |
|---|---|---|
| RFP 75D301-20-R-68127.pdf | ||
| Att D - Question and Answer Template.xlsx | XLSX spreadsheet | |
| Att B - Task Deliverables Table.xlsx | XLSX spreadsheet | |
| Att C - Pricing Table.xlsx | XLSX spreadsheet | |
| Att A - Offeror Capabilities and Specimens.xlsx | XLSX spreadsheet |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Q301--Blood Donor Panel Testing for Captain James A. Lovell Federal Health Care Center (FHCC) | Veterans Integrated Service Network 12 | No set-aside | |
| RFP-797-FSS-04-0001-R3: 621II Medical Laboratory Testing & Analysis Services | Veterans Integrated Service Network 12 | No set-aside | |
| Laboratory Support Services | Washington Headquarters Service | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity